Impact of Ketoflex 12/3 Diet on Early-to-Mid Stage Alzheimer's Progression

NACompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

March 1, 2024

Primary Completion Date

September 30, 2024

Study Completion Date

October 31, 2024

Conditions

Alzheimer Type DementiaAlzheimer's Disease (AD)

Interventions

BEHAVIORAL

Ketoflex 12/3 Diet

plant-based ketogenic diet combined with intermittent fasting (12/3)

Trial Locations (1)

Istanbul Medipol Universitesi, Istanbul

All Listed Sponsors

lead

Prof. Lutfu Hanoglu, MD

OTHER

NCT06898424 - Impact of Ketoflex 12/3 Diet on Early-to-Mid Stage Alzheimer's Progression | Biotech Hunter | Biotech Hunter